Polyclonal rabbit antisera were produced against cyclic human inhibin [(Cys6, Tyr7)a-(6-30)NH2] peptide, covalently conjugated to bovine serum albumin. The tyrosine residue introduced at position 7 facilitated the oxidative incorporation of radiolabel (1251) to yield a tracer with specific activity of 73.9 Ci/g. These reagents were used to develop a homologous equilibrium radioimmunoassay for human inhibin, with polyethylene glycol, 200 g/L, serving as the separation phase. At a detection limit of 2 /L (n = 7), immunoactive inhibin was detectable in human pre-ovulatory follicular fluid (128 g/L), seminal plasma (2374 g/L), amniotic fluid (66 .tg/L), and placental extract (347 g/L). We also demonstrated inhibin immunoreactivity in biological fluids from other mammalian species: macaque, chimpanzee, porcine, and bovine, but not rodent (guinea pig). Although the antisera were raised against a nonbioactive inhibin peptide, immunoglobulins fractionated on Protein A-Sepharose neutralized the bioactivity of human ovarian inhibin. (17) . Despite limited immunological cross-reactivity (30%) between bovine and human inhibin, this assay was used to quantify concentrations of human inhibin within one order of magnitude above the assay detection limit.
Radioimmunoassay of Inhibin Based on Synthetic Human Inhibin a-Chain Peptide
Polyclonal rabbit antisera were produced against cyclic human inhibin [(Cys6, Tyr7)a-(6-30)NH2] peptide, covalently conjugated to bovine serum albumin. The tyrosine residue introduced at position 7 facilitated the oxidative incorporation of radiolabel (1251) to yield a tracer with specific activity of 73.9 Ci/g. These reagents were used to develop a homologous equilibrium radioimmunoassay for human inhibin, with polyethylene glycol, 200 g/L, serving as the separation phase. At a detection limit of 2 /L (n = 7), immunoactive inhibin was detectable in human pre-ovulatory follicular fluid (128 g/L), seminal plasma (2374 g/L), amniotic fluid (66 .tg/L), and placental extract (347 g/L). We also demonstrated inhibin immunoreactivity in biological fluids from other mammalian species: macaque, chimpanzee, porcine, and bovine, but not rodent (guinea pig). Although the antisera were raised against a nonbioactive inhibin peptide, immunoglobulins fractionated on Protein A-Sepharose neutralized the bioactivity of human ovarian inhibin. Further characterization of inhibin immuno-and bioactivity was undertaken with immobilized heparin, divalent metal cations, and dye ligands. Only heparin-Sepharose distinguished between immuno-and bioactive inhibin. Since the initial hypothesis of a gonadal secretagogue to modulate pituitary cell function (1,2), much research effort and resources have been invested to identify and isolate the causative agent, termed inhibin. Inhibin was defined as a gonadal hormone, found in males and females, that selectively suppressed secretion of follitropin (FSH) by the pituitary gland (3)5 Detection of inhibin was limited to bioassays, an in vitro activity associated with compounds of heterogeneous molecular size (4). In 1985 porcine inhibin was purified to homogeneity (5, 6) , and complementary deoxynucleic acid (cDNA) coding for the messenger ribonucleic acid (mRNA) of human ovarian inhibin was reported (7, 8 (3, 13, 14) . However, because of their polyspecificities, these antisera cannot be used to quantify inhibin. The first inhibin radioimmunoassay (RIA) was based on antigen isolated from human seminal plasma (15) ; however, the authors failed to establish assay specificity. McLachlan et al. (16) described an RIA based on the use of bovine follicular inhibin (Mr 31 000 and 58 000) and polyclonal rabbit antisera that, without selective absorption, apparently recognized only inhibin a-chain (17) . Despite limited immunological cross-reactivity (30%) between bovine and human inhibin, this assay was used to quantify concentrations of human inhibin within one order of magnitude above the assay detection limit.
In this study we developed and characterized a homologous RIA for human inhibin based on a synthetic peptide prepared from sequence analysis of human ovarian inhibin a-chain (1, 8).
Materials and Methods
Cyclic human inhibin [(Cys6, Tyr7) a-(6-30)NH2; Code No. 145-198-3G-54-67] was prepared at The Salk Institute, San Diego, CA. The peptide was cyclicized by coupling the sulfhydryl bond of the cysteines at amino acid positions 6 and 30. A tyrosine residue was introduced at position 7 to facilitate the incorporation of radioisotopic iodine (1251). Human inhibin a-chain peptide was coupled to bovine serum albumin (BSA) via bis-diazotized benzidine for immunization.
The synthetic cyclic peptide was diluted in 50 mmol/L sodium phosphate buffer, pH 7.4, to give a 1 g/L solution. 1 (19) .
Biological Samples
Human pre-ovulatory follicular fluid (hFF) was obtained from women (n >100 (Figure 1) . At immunoglobulin doses <10 g, there was no significant decrease in bioactivity.
Almost 75% of the added 1I was incorporated into the synthetic inhibin a-chain peptide, resulting in a specific activity of 73.9 CiJg. All five rabbits produced antisera that reacted with '251-labeled inhibin a-chain peptide (free and BSA-conjugated) and with 125I-labeled BSA. After overnightabsorption with BSA, these specificities were removed without influencinginhibin immunoreactivity.
Qualitatively, these antisera displayed similar characteristics in the RIA (Table 1) . At fixed doses of 1.5 mg of irnmunoglobulins per 400 zL of hFF, all five antiinhibin antisera neutralized the bioactivity of human ovarian inhibin. The antiserum from rabbit 3 was used (61.9 mg) co-eluted with inhibin, 34.4% of which reversibly interacted with the ligand (Table 3) . With all ligands studied, the inhibin that bound to each matrix retaineditsbioactivity after desorption.
Chromatography of IIFF (40 mL) on a preparative 40-mL column of heparin-Sepharose in low-ionic- During sample application, 6-mL fractions were collected; thereafter, 3-mL fractions were collected (12.1%), such that it co-eluted with heparin-noninteracting proteins in equilibration buffer containing 0.15 mol of NaCl per liter.
By chromatographing equilibration buffer, as for hFF, we provided a direct control for assessing ligand-matrix interaction.
Using (Figure 4) .
DiscussIon
Since the isolation and biochemical characterization of inhibin molecules, porcine inhibin peptides, 6-30 amino acid residues from the amino terminal of the a-chain, have been designed and synthesized. In earlier studies these derivatives were used to prepare polyclonal rabbit antisera for immunological detection of inhibin (6, (22) (23) (24) . In The dilution curves for these fluids did not display parallelism, suggesting differences in the amino acid composition and (or) carbohydrate microheterogeneity of inhibin. By contrast, follicular inhibin immunoreactivity was conserved among the mammalian species .4 studied, supporting earlier inhibin sequence studies (7, 12). Immunological cross-reactivity was also detected with other synthetic inhibin peptides (A chain 1-32 peptide; Peninsula), which suggests that this assay may prove useful in measuring synthetic analogs of inhibin. The RIA we developed may also be applied to human, nonhuman primate ( or a combination of these methods.
Note that the immunological and functional properties of heparin-noninteracting inhibin were distinct from heparin-binding inhibin and unfractionated follicular fluid. This raises concerns over the physiological significance of low concentrations of apparent inhibin iinmunoreactivity, generated by heterologous inhibin immunoassays (25) in earlier clinical studies (17) . First, suppression of the binding of labeled inhibin peptide by the primary antibody may not be solely due to bioactive inhibin, but may in part also be attributed to other cross-reacting antigens. Second, the degree of interference by these other antigens is determined by their relative concentration, which may vary from tissue to tissue and depend on hormonal status. Third, with this scenario it seems unlikely that direct immunological analysis would provide a meaningful indication of inhibin bioactivity and hence be of any clinical significance. Investigators should be wary of these potential limitations, particularly when undertaking immunohistochemical studies. 
